News
Chelverton UK Dividend Trust plc: Net Asset Value(s)
Chelverton UK Dividend Trust plc: Net Asset Value(s)
Form 8.3 - The Vanguard Group, Inc.: Brewin Dolphin Holdings plc
Form 8.3 - The Vanguard Group, Inc.: Brewin Dolphin Holdings plc
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
DGAP-Adhoc: Eckert & Ziegler Lowers 2022 Profit Guidance to 27 mm EUR
DGAP-Adhoc: Eckert & Ziegler Lowers 2022 Profit Guidance to 27 mm EUR
Rights and Issues Investment Trust PLC: Net Asset Value(s)
Rights and Issues Investment Trust PLC: Net Asset Value(s)
Dalata Hotel Group PLC: Block Listing Interim Review
Dalata Hotel Group PLC: Block Listing Interim Review
DGAP-News: Nabaltec AG receives the Gold Seal for Family-Friendly Businesses in the County of Schwandorf
DGAP-News: Nabaltec AG receives the Gold Seal for Family-Friendly Businesses in the County of Schwandorf
DGAP-Adhoc: EnviTec Biogas AG raises earnings forecast for fiscal year 2022
DGAP-Adhoc: EnviTec Biogas AG raises earnings forecast for fiscal year 2022
DGAP-News: ProCredit Holding seeks to further optimise its funding position by offering debt investors term amendments
DGAP-News: ProCredit Holding seeks to further optimise its funding position by offering debt investors term amendments
DGAP-Adhoc: ProCredit AG & Co. KGaA is considering amendments to the conditions of outstanding bonds by majority resolutions of the holders or by contractual agreements, including the possible payment of a fee
DGAP-Adhoc: ProCredit AG & Co. KGaA is considering amendments to the conditions of outstanding bonds by majority resolutions of the holders or by contractual agreements, including the possible payment of a fee
Poxel Announces the Publication of Two Preclinical Articles on X-Linked Adrenoleukodystrophy for PXL065 and PXL770
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
DGAP-News: The clamshell is back: Gigaset presents 4G GSM mobile phone GL7. Smart form factor, smart features - the new mobile device combines two worlds
DGAP-News: The clamshell is back: Gigaset presents 4G GSM mobile phone GL7. Smart form factor, smart features - the new mobile device combines two worlds
DGAP-News: GORE German Office Real Estate AG: Three office properties successfully sold in Ratingen
DGAP-News: GORE German Office Real Estate AG: Three office properties successfully sold in Ratingen
DGAP-News: publity AG successfully sells three properties in Ratingen
DGAP-News: publity AG successfully sells three properties in Ratingen
DGAP-News: init innovation in traffic systems SE: Status of the share buyback 27 June – 1 July 2022
DGAP-News: init innovation in traffic systems SE: Status of the share buyback 27 June – 1 July 2022
Elliptic Labs Launches with Xiaomi on Xiaomi 12S Ultra and 12 Pro Smartphones for China Market
Elliptic Labs (OSE: ELABS), a global AI software company and the world leader in AI Virtual Smart Sensors™, has launched its AI Virtual Proximity Sensor™ INNER BEAUTY® on the Xiaomi 12S Ultra and
Pharnext Appoints Antoine Gravelle as General Counsel
Pharnext Appoints Antoine Gravelle as General Counsel
DGAP-News: MPC Capital further expands commitment to the decarbonization of the shipping industry
DGAP-News: MPC Capital further expands commitment to the decarbonization of the shipping industry
R.E.A. Holdings plc: Notification of Major Holdings
R.E.A. Holdings plc: Notification of Major Holdings
DGAP-News: Defence Therapeutics Inc.: DEFENCE’S ACCUMTM WITH ANTIBODY DRUG CONJUGATES (ADC) IN DEVELOPMENT AGAINST CANCER
DGAP-News: Defence Therapeutics Inc.: DEFENCE’S ACCUMTM WITH ANTIBODY DRUG CONJUGATES (ADC) IN DEVELOPMENT AGAINST CANCER